Treatment Experience Using a Micro‐Induction Buprenorphine Protocol for Chronic Pain in Pediatric Sickle Cell Disease
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31731 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Ashwin Patel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Buprenorphine, Chronic Pain, Analgesics, Opioid. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Schmerzmanagement
Abstract (Originalsprache)
Background
Patients with sickle cell disease (SCD) experience painful vaso‐occlusive episodes that increase with age; a subset develops chronic pain (CP). CP is usually managed with acute pain management guidelines despite evidence of ineffectiveness. Buprenorphine (BUP), a partial opioid agonist, is a potent analgesic with less euphoric effect and a respiratory “ceiling effect.” BUP therefore provides an alternative “harm reduction” approach for CP management in pediatric SCD patients.
Methods
This single urban center retrospective study assessed the feasibility of inpatient transition to BUP‐containing analgesics in adolescents with SCD and CP. Patients aged 12–20 years who transitioned from full opioid agonists (FOA) to BUP between December 2020 and September 2022 were included. Acute care utilization, hospital length of stay, and FOA use in both inpatient and outpatient settings were compared pre‐ and post‐BUP induction for up to a year.
Results
Fourteen adolescents with SCD underwent inpatient BUP induction and maintenance therapy. Inpatient transition using a micro‐induction approach was feasible and well tolerated in this population. There were low rates of adverse events, such as opioid withdrawal signs. Maintenance on BUP products was sustainable over the 1‐year post‐induction period. Three patients (21%) discontinued BUP during maintenance therapy. There was a significant reduction ( p < 0.05) in acute care utilization, length of stay, and FOA use (both inpatient and outpatient).
Conclusion
Inpatient micro‐induction to BUP from FOA in adolescent SCD patients with CP is feasible with minimal signs of opioid withdrawal. This study suggests decreased acute care utilization with BUP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Emory University School of Medicine, Atlanta, Georgia, USA.
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
- Novo Nordisk Rare Disease, Zurich, Switzerland.
- Johns Hopkins All Children's Hospital, St Petersburg, Florida, USA.
ORCID-Profile: Ashwin Patel, Carlton Dampier, Tamara New, Elna Saah
Zitieren
APA
Patel, A., Kalmus, G., Dampier, C., Osunkwo, I., New, T., Gee, B., & Saah, E. (2025). Treatment Experience Using a Micro‐Induction Buprenorphine Protocol for Chronic Pain in Pediatric Sickle Cell Disease. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31731
Vancouver
Patel A, Kalmus G, Dampier C, Osunkwo I, New T, Gee B, et al. Treatment Experience Using a Micro‐Induction Buprenorphine Protocol for Chronic Pain in Pediatric Sickle Cell Disease. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31731
BibTeX
@article{Patel2025,
author = {Patel, Ashwin and Kalmus, Grace and Dampier, Carlton and Osunkwo, Ifeyinwa and New, Tamara and Gee, Beatrice and Saah, Elna},
title = {Treatment Experience Using a Micro‐Induction Buprenorphine Protocol for Chronic Pain in Pediatric Sickle Cell Disease},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31731}
}
EUVIMED